Biohaven Ltd. (NYSE:BHVN) is ARS Investment Partners LLC’s 6th Largest Position

ARS Investment Partners LLC increased its position in shares of Biohaven Ltd. (NYSE:BHVN) by 1.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,040,712 shares of the company’s stock after purchasing an additional 10,473 shares during the quarter. Biohaven comprises approximately 3.5% of ARS Investment Partners LLC’s investment portfolio, making the stock its 6th biggest position. ARS Investment Partners LLC’s holdings in Biohaven were worth $38,871,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. Farallon Capital Management LLC increased its holdings in Biohaven by 181.4% during the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock worth $78,028,000 after purchasing an additional 1,449,000 shares during the period. Point72 Asset Management L.P. lifted its stake in Biohaven by 745.9% in the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after acquiring an additional 1,322,922 shares during the period. Armistice Capital LLC increased its position in Biohaven by 74.8% during the 2nd quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock valued at $48,489,000 after purchasing an additional 597,705 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Biohaven by 563.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock valued at $25,416,000 after purchasing an additional 431,954 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Biohaven by 85.4% during the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock valued at $40,448,000 after purchasing an additional 372,737 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BHVN. Robert W. Baird upped their target price on Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Piper Sandler raised their price target on shares of Biohaven from $66.00 to $76.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective (up previously from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. Finally, TD Cowen upped their price objective on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Thirteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $63.00.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $37.57 on Tuesday. The business’s 50 day moving average price is $41.03 and its 200-day moving average price is $42.40. The firm has a market capitalization of $3.80 billion, a PE ratio of -4.02 and a beta of 1.29. Biohaven Ltd. has a 1 year low of $26.80 and a 1 year high of $62.21.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, analysts expect that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Insiders Place Their Bets

In other Biohaven news, Director John W. Childs bought 29,000 shares of Biohaven stock in a transaction on Monday, December 30th. The shares were bought at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the transaction, the director now directly owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. This trade represents a 1.24 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 16.00% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.